Biotech Deals, Spanish Surge, Vaccine Breakthroughs
Kilder
- STAT: STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- Bostonglobe: GSK to buy Cambridge-based Nuvalent, maker of targeted cancer drugs, for $10.6 billion - The Boston Globe
- Raps: Recon: GSK to buy Nuvalent for $10.6B; Pentagon labels WuXi AppTec as linked to Chinese military - RAPS.org
- GEN: T-Cell Synapse Formation Is Restrained by PTPN22–PSTPIP1 Signaling
- GEN: First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine Data - Genetic Engineering and Biotechnology News
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.